Leerink Partners analyst Jonathan Chang reiterated a Buy rating on Immatics (IMTX – Research Report) on October 11 and set a price target ...

Lundbeck A/S is to acquire Longboard Pharmaceuticals Inc. in an all-cash deal valuing the epilepsy specialist at $2.6 billion. The agreed price of $60 per share is a 54% premium to the closing price ...

Immatics, a biotech company working on promising cell-based immunotherapies for solid cancers, has a promising TCR-engineered ...

The firm plans to use the proceeds to advance its pipeline of T-cell receptor therapies and support their manufacturing, production, and commercialization.

September 2024's negative private sector balance of -$70 billion suggests a likely decline in risk asset markets into October ...

The firm is gearing up for a registration-directed trial based on a positive Phase Ib readout and after discussions with US ...

German cancer specialist Immatics has priced a $150 million public offering with Jefferies, BofA Securities, and Leerink as ...

EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T ...

Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development ...

PDUFA date, the U.S. FDA has approved Genentech Inc.’s first-line breast cancer treatment Itovebi (inavolisib). Itovebi is to be combined with Pfizer Inc.’s palbociclib (Ibrance) and fulvestrant for ...

On Thursday, Immatics N.V. (NASDAQ:IMTX) stock is trading lower after the company commenced an underwritten public offering ...

Immatics said its PRAME-targeted T cell therapy shrank tumors by at least 30% in just over half of melanoma patients in an ...